Anbenitamab Plus Docetaxel Beats THP in HER2-Positive Breast Cancer Trial

A phase 3 randomized trial in China compared anbenitamab plus albumin-bound docetaxel (HB1801) with the standard docetaxel-trastuzumab-pertuzumab (THP) regimen in 885 patients with HER2-positive advanced breast cancer. The trial reported estimated 24-month progression-free survival of 58.5% with anbenitamab plus HB1801 versus 34.4% with THP (hazard ratio 0.46), along with higher objective response rates (87.6% vs 73.4%) but also more grade 3 or higher adverse events (45.9% vs 34.4%), most commonly neutropenia.

Most relevant for: Patients with HER2-positive advanced breast cancer being considered for first-line systemic therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.